New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:34 EDTNBYNovaBay announces completion of enrollment in Phase 2 BAYnovation trial
NovaBay announced it has completed enrollment of patients in its global Phase 2b viral conjunctivitis trial, BAYnovation. The trial is investigating NovaBay’s Auriclosene -- NVC-422 -- Ophthalmic Solution as a treatment for adenoviral conjunctivitis, a highly contagious, potentially sight-impairing form of “pink eye”. This condition affects millions of people globally and there is currently no approved treatment available anywhere in the world. NovaBay expects to report results from its trial in mid-2014. BAYnovation is a multi-centered, randomized clinical study that has enrolled patients with adenoviral conjunctivitis in the United States, India, Sri Lanka, and Brazil. Patients were enrolled into the study by 54 clinical investigators, including 18 in the US, 19 in India, 6 in Sri Lanka and 11 in Brazil. BAYnovation was designed to evaluate the efficacy of NovaBay’s Auriclosene Ophthalmic Solution in the treatment of adenoviral infection, specifically clearing the associated red eye and reducing lingering effects left by the infection.
News For NBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
08:23 EDTNBYNovaBay to hold a conference call
Subscribe for More Information
January 20, 2015
07:06 EDTNBYNovaBay expanding sales force for Avenova
NovaBay Pharmaceuticals announced that it is expanding its sales force for its innovative eye care product Avenova from 15 sales representatives to 35 representatives. Ron Najafi, Ph.D., Chairman and CEO of NovaBay, commented, “We plan to further increase our sales force to more than 50 representatives by July, which will allow us to reach more of the estimated 30 million Americans who suffer from eyelid conditions. We estimate the market opportunity for Avenova at $500 million annually in the U.S. alone.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use